Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lennar Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.11 (market cap $29.60B), while Lennar Corporation trades at $85.88 (market cap $21.05B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Lennar Corporation pays a 2.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LEN | |
|---|---|---|
Market Cap | $29.60B | $21.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $142.40 |
52-Week Low | $205.48 | $81.84 |
Enterprise Value | $27.56B | $24.93B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Lennar (LEN) trades at $85.6, down 2.93% on the day, with a bearish technical signal from moving averages and recent earnings misses. The stock appears fundamentally undervalued with a P/E of 13.72 and P/S of 0.66, but faces headwinds from declining revenue and net income margins, which fell to 4.93% in 2025. A new housing affordability law offers a potential catalyst, while high mortgage rates and competitive pressures from disruptors like Boxabl present challenges.
The outlook is mixed; valuation metrics suggest upside potential, but weakening profitability and a bearish technical trend warrant caution. The consensus price target of $84.30 implies limited near-term growth, with investment opportunity hinging on a housing market recovery and execution against margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
